Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741092 | 0.92 | DAGLA (0.41) | SLC6A9CYP2C19PPARGPPARACTSS | |
| SCHEMBL20741091 | 0.92 | DAGLA (0.41) | SLC6A9CYP2C19PPARGPPARACTSS | |
| SCHEMBL1221765 | 0.89 | PTGS2 (0.39) | PTGS2MMP12CTSSCTSK | |
| SCHEMBL24726844 | 0.82 | ALOX5 (0.40) | MAPTCTSSCTSK | |
| SCHEMBL2953235 | 0.82 | PTGS2 (0.47) | PTGS2CYP2C9CYP2C19CTSSCTSK | |
| SCHEMBL20741069 | 0.80 | CASR (0.41) | MAPTCTSSCTSK | |
| SCHEMBL20741070 | 0.80 | CASR (0.41) | MAPTCTSSCTSK | |
| SCHEMBL20741072 | 0.79 | MTOR (0.40) | CTSSCTSK | |
| SCHEMBL20741073 | 0.79 | MTOR (0.40) | CTSSCTSK | |
| SCHEMBL9190936 | 0.76 | MAOB (0.48) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046134-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | BISCHOFF ALEXANDER | 2011-02-24 | — | — | US | disclosed |
| US-20110046134-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | BISCHOFF ALEXANDER | 2011-02-24 | — | — | US | disclosed |
| US-20110046134-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | BISCHOFF ALEXANDER | 2011-02-24 | — | — | US | disclosed |
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | disclosed |
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | disclosed |
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | disclosed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | disclosed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | disclosed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | disclosed |
| WO-2008157844-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157844-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046134-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | PTGS2 559/4885SLC6A9 4844/4885ALDH1A1 969/4885 |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | PTGS2 559/4885SLC6A9 4844/4885ALDH1A1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.